Insider Buying: Boston Scientific (NYSE:BSX) Director Acquires $227,400.00 in Stock

Boston Scientific Corporation (NYSE:BSX) Director Edward Ludwig bought 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Boston Scientific Trading Up 3.7%

Shares of NYSE BSX traded up $1.73 during trading on Monday, reaching $48.45. The company had a trading volume of 20,362,834 shares, compared to its average volume of 18,391,215. The company’s fifty day moving average price is $46.13 and its 200-day moving average price is $62.02. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The stock has a market cap of $72.02 billion, a P/E ratio of 19.62, a PEG ratio of 1.02 and a beta of 0.56. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The business’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has approved a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Institutional Trading of Boston Scientific

Hedge funds have recently modified their holdings of the stock. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific in the fourth quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd bought a new stake in Boston Scientific in the first quarter valued at $28,000. Finally, Sfam LLC bought a new stake in Boston Scientific in the fourth quarter valued at $29,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BSX shares. Raymond James Financial restated an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a report on Thursday. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a research report on Thursday. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Stifel Nicolaus set a $60.00 target price on shares of Boston Scientific in a report on Wednesday. Finally, Truist Financial cut their price target on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.